We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+33.7%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.99B
AUM Growth
-$172M
Cap. Flow
+$217M
Cap. Flow %
10.88%
Top 10 Hldgs %
59.05%
Holding
53
New
18
Increased
6
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$68.6M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$55M
3
DMRA
Damora Therapeutics
DMRA
+$39.2M
4
AGMB
AgomAb Therapeutics NV
AGMB
+$34.9M
5
MAZE
Maze Therapeutics
MAZE
+$33.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$69.8M
2
ENGN icon
enGene Therapeutics
ENGN
+$36.1M
3
BBIO icon
BridgeBio Pharma
BBIO
+$25.4M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$20M
5
GHRS icon
GH Research
GHRS
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0.66%
3 Miscellaneous 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
51
Janux Therapeutics
JANX
$1.1B
– –
-650,000
Closed -$8.97M
QQQ icon
52
PUT
Invesco QQQ Trust
QQQ
$489B
– –
-250,000
Closed -$154M
XBI icon
53
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-1,000,000
Closed -$122M
1 2
3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Cormorant Asset Management held 53 positions worth $1.99B, down 7.9% from $2.16B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management deployed $217M of net new capital in Q1 2026, opening 18 new positions and adding to 6 existing holdings. Its largest new stake was Erasca: 5,800,000 shares worth $93.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 82% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Abivax, an estimated $69.8M trimmed.

  • Cormorant Asset Management's largest Q1 2026 buy was Erasca: 5,800,000 shares worth $93.8M.
  • Cormorant Asset Management added most to Olema Pharmaceuticals in Q1 2026, an estimated $25.6M increase.
  • Cormorant Asset Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $69.8M.
  • Cormorant Asset Management fully exited enGene Therapeutics in Q1 2026, selling an estimated $36.1M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.99B portfolio in Q1 2026.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q1 2026.
  • Cormorant Asset Management's portfolio value fell 7.9% quarter-over-quarter to $1.99B.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.